Ultragenyx Pharmaceutical Inc.(RARE)Earnings, Financials & Key RatiosUltragenyx Pharmaceutical Inc. (RARE) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to achieve operating leverage, combined with a negative equity position of $236.0M and a shrinking cash balance, suggests significant ongoing dilution and liquidity risks for investors.
Ultragenyx Pharmaceutical Inc. (RARE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Ultragenyx Pharmaceutical Inc. (RARE) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.84vs $1.49-23.7% | $136Mvs $158M-14.0% |
| Q1 2026 | Feb 12, 2026 | $1.29vs $1.20-7.5% | $207Mvs $199M+4.2% |
| Q4 2025 | Nov 4, 2025 | $1.81vs $1.23-47.2% | $160Mvs $200M-19.9% |
| Q3 2025 | Aug 5, 2025 | $1.17vs $1.27+7.9% | $166Mvs $166M+0.3% |
Recent stock market news and headlines for Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ultragenyx (RARE) is transitioning from a broad pipeline to a focused rare disease platform, entering a high-catalyst period with four approved products and multiple late-stage assets. Despite a recent Phase 3 failure and Q1 2026 net loss, RARE reaffirmed 2026 revenue guidance of $730–$760 million, supported by a scalable commercial base and cost controls. Key near-term catalysts include FDA reviews for DTX401 and UX111 (PDUFA dates in H2 2026) and pivotal Phase 3 Aspire results for GTX-102 in Angelman syndrome.
NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company's common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
NOVATO, Calif. , June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company's common stock to 15 newly hired non-executive officers of the company.
Key metrics vs top competitors for Ultragenyx Pharmaceutical Inc. (RARE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $35.87 | $3.53B | -6.15 | 20.13% | -85.44% | -607.51% | — | |
| $60.35 | $11.61B | 33.53 | 12.87% | 8.29% | 4.41% | — | |
| $19.79 | $2.09B | -2.78 | 15.58% | 2.98% | 4.89% | — | |
| $86.33 | $14.27B | -36.27 | 33.87% | -30.87% | -58.57% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — |
Ultragenyx Pharmaceutical Inc. (RARE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Ultragenyx Pharmaceutical Inc. (RARE) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Apr 2, 2026·SEC
Mar 30, 2026·SEC
Get notified when RARE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ultragenyx Pharmaceutical Inc. (RARE) stock FAQ — growth, dividends, profitability & financials explained
Ultragenyx Pharmaceutical Inc. (RARE) reported $669.4M in revenue for fiscal year 2025.
Ultragenyx Pharmaceutical Inc. (RARE) grew revenue by 20.1% over the past year. This is strong growth.
Ultragenyx Pharmaceutical Inc. (RARE) reported a net loss of $609.4M for fiscal year 2025.
Ultragenyx Pharmaceutical Inc. (RARE) has a return on equity (ROE) of -607.5%. Negative ROE indicates the company is unprofitable.
Ultragenyx Pharmaceutical Inc. (RARE) had negative free cash flow of $487.2M in fiscal year 2025, likely due to heavy capital investments.
